Benitec said that its CFO John Rawling will resign on Aug. 24.
He will be replaced by Greg West.
The company said that Rawling's departure is related to the company's relocation to Sydney from Melbourne, Australia.
The application claims “novel synthetic genes and genetic constructs which are capable of repressing, delaying, or otherwise reducing the expression of an endogenous gene or a target gene in an organism.”
"Together with the favorable ruling by the US Patent and Trademark Office late last year, and other favorable decisions since, including in Europe, this [financing] enables the relaunch of Benitec,” CEO Peter French said in a statement.
Although it was one of the earliest patents in the RNAi field, the IP had earlier been deemed invalid by the USPTO after re-examination proceedings were initiated by now-defunct expressed RNAi firm Nucleonics.